[Amoxycillin/potassium clavulanate in inpatients with bronchopulmonary infections].

  title={[Amoxycillin/potassium clavulanate in inpatients with bronchopulmonary infections].},
  author={Vladimir Nonikov and T D Konstantinova and N I Lenkova and V. I. Minaev and L A Ritchik},
  journal={Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]},
  volume={42 10},
Step-by-step therapy of patients with pneumonia and exacerbated chronic bronchitis with amoxyclav (amoxycillin/potassium clavulanate) in a dose of 1.2 g administered intravenously dropwise every 8 hours for the first 2 days of the treatment with subsequent oral use of the drug in a dose of 625 mg thrice a day for 5 days proved to be highly efficient. The recovery and improvement were stated in 19 (95 per cent) out of 20 patients. The adverse reaction (urticaria) was observed in 1 patient… CONTINUE READING